Answers are grounded in this paper and cite their sources.
Systematic case study reviews treatment complications of immune checkpoint inhibitors in myocarditis cases, indicating unresolved diagnostic challenges.
Myocarditis is a life-threatening complication of immune checkpoint inhibitor therapy. Over the past ten years, drugs in this group have been used in the treatment of a wide range of hematological diseases and solid tumors. With steadily growing life expectancy of cancer patients, problems associated with treatment complications are increasingly coming to the fore. Since 2016, publications have appeared on cases of autoimmune myocarditis during checkpoint inhibitor therapy (CIT), among which there are quite a few single-center retrospective and observational studies. At the same time, the problem of diagnosis and treatment of immune checkpoint inhibitor myocarditis remains unresolved.This paper presents a review on the problem of immune checkpoint inhibitor myocarditis, as well as the results of a systematic analysis of PubMed database publications.
No takes yet. Share an insight, caveat, or question.
Кушнарева et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: